Cumberland Pharmaceuticals (CPIX)
(Delayed Data from NSDQ)
$1.25 USD
-0.03 (-2.34%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $1.26 +0.01 (0.80%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Cumberland Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 40 | 42 | 36 | 37 | 48 |
Cost Of Goods | 6 | 9 | 9 | 9 | 9 |
Gross Profit | 33 | 33 | 27 | 29 | 39 |
Selling & Adminstrative & Depr. & Amort Expenses | 43 | 39 | 35 | 35 | 42 |
Income After Depreciation & Amortization | -10 | -6 | -8 | -6 | -4 |
Non-Operating Income | 4 | 1 | 2 | 0 | 0 |
Interest Expense | 1 | 1 | 0 | 0 | 0 |
Pretax Income | -6 | -6 | -6 | -7 | -4 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -6 | -6 | -6 | -7 | -4 |
Extras & Discontinued Operations | 0 | 0 | 2 | 3 | 0 |
Net Income (GAAP) | -6 | -6 | -4 | -3 | -4 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -1 | 0 | -3 | -2 | 1 |
Depreciation & Amortization (Cash Flow) | 8 | 5 | 5 | 5 | 4 |
Income After Depreciation & Amortization | -10 | -6 | -8 | -6 | -4 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 14.30 | 14.56 | 14.91 | 15.16 | 15.40 |
Diluted EPS Before Non-Recurring Items | 0.14 | 0.11 | -0.01 | -0.06 | 0.23 |
Diluted Net EPS (GAAP) | -0.44 | -0.38 | -0.24 | -0.22 | -0.23 |
Fiscal Year end for Cumberland Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 9.85 | 8.50 | 9.35 | 10.09 | 10.89 |
Cost Of Goods | 1.71 | 1.58 | 1.53 | 1.77 | 1.52 |
Gross Profit | 8.14 | 6.92 | 7.82 | 8.32 | 9.37 |
SG&A, R&D, and Dept/Amort Expenses | 9.17 | 8.79 | 14.00 | 10.19 | 9.35 |
Income After SG&A, R&D, and Dept/Amort Expenses | -1.03 | -1.87 | -6.18 | -1.87 | 0.02 |
Non-Operating Income | 0.06 | 0.10 | 0.08 | 0.92 | 1.04 |
Interest Expense | 0.13 | 0.12 | 0.18 | 0.11 | 0.19 |
Pretax Income | -1.09 | -1.89 | -6.28 | -1.06 | 0.87 |
Income Taxes | 0.01 | 0.01 | 0.04 | -0.01 | 0.01 |
Minority Interest | -0.02 | 0.04 | -0.01 | -0.01 | -0.01 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -1.10 | -1.90 | -6.32 | -1.05 | 0.86 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -1.09 | -1.95 | -6.29 | -1.05 | 0.87 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 14.12 | 14.10 | 14.16 | 14.28 | 14.55 |
Diluted EPS Before Non-Recurring Items | 0.00 | -0.06 | -0.12 | 0.02 | 0.15 |
Diluted Net EPS (GAAP) | -0.08 | -0.14 | -0.44 | -0.07 | 0.06 |